Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Aeterna Zentaris GmbH is most often covered alongside COSCIENS Biopharma Inc., which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Aeterna Zentaris GmbH is most often covered alongside COSCIENS Biopharma Inc., which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.8. Aeterna Zentaris GmbH appears in 1 tracked Healthcare story from March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Aeterna Zentaris GmbH. Shared-story counts are live from our verified record — not editorial picks.
Strategic Update
COSCIENS announces cessation of funding for German subsidiaries and expected insolvency.
FDA Type C Meeting
Company meets with FDA to discuss disappointing DETECT trial results and pediatric path forward.
DETECT Trial Results
Phase 3 trial for Macrilen pediatric indication fails to meet primary endpoints.
Wuzhou Distribution Deal
COSCIENS signs distribution agreement with Wuzhou Drug International Trading Limited.
COSCIENS Biopharma Inc. (TSX: CSCI) has announced a strategic cessation of funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, effectively triggering an insolvency process. This decision follows a critical failure in the Phase 3 DETECT trial for Macrilen’s pediatric indication and a subsequent setback in FDA negotiations.
Source: GlobeNewswire (ca) · CBJ (ca)
Aeterna Zentaris GmbH is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
